Form D · Biotechnology
Alphyn Biologics, Inc.
Annapolis, MD · CIK 0001802325
Offering snapshot reported May 20, 2024 · SEC filing
- Reported sold
- $1.19M Offering amount: $1.76M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2024 | Initial | $1,185,717 | No comparison | 17 | SEC filing |
| Apr 15, 2024 | Initial | $5,172,484 | No comparison | 18 | SEC filing |
| May 23, 2022 | Initial | $2,169,997 | No comparison | 7 | SEC filing |
| Feb 6, 2020 | Initial | $800,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513699
Source: Form D, filed May 20, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Roger Griggs | Director |
| Neal Koller | Director, Executive |
| Jeffrey Kossak | Director |
| Adel Mikhail | Director |
| Gary Pekoe | Director, Executive |
| Steven Pentelnik | Executive |
| Tony Shipley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3724 Thomas Point Road
Annapolis, MD, 21403
Annapolis, MD, 21403